News | January 04, 2009

Micro-Bubble Echo Contrast Procedures Rebounded in 2008

January 5, 2009 - Arlington Medical Resources (AMR), a provider of market intelligence for the pharmaceutical and diagnostic imaging industries, reported that the number of micro-bubble echo contrast procedures performed in October 2008 have increased by more than 50 percent, to nearly 18,000 procedures, when compared to May 2008.

Micro-bubble echo contrast procedures began declining sharply in October 2007, from nearly 55,000 procedures in September 2007, as a result of a black box warning issued by the FDA in October 2007.

A revised black box warning issued in May 2008 has contributed to this rebound as well as physicians and sonographers reestablishing protocols for contrast usage in their institutions. A micro-bubble echo contrast agent is administered intravenously and used for contrast enhancement during echocardiographic procedures.

The newly released edition of the U.S. Echocardiography Monthly Monitor also finds that both Lantheus Medical Imaging's Definity and GE Healthcare's Optison - the two FDA approved micro-bubble echo contrast agents - realized increased usage during the same study period.

For more information: www.AMR-data.com

Related Content

Iodine-based CT contrast with ready for scanning with a Canon Aquilion One 320-slice CT system at Northwestern Medicine Central DuPage Hospital in the Chicago suburbs. It is not clear that contrast caused contract induced nephrapathy (CIN), also referred to as acute kidney injury (AKI) or contrast-associated acute kidney injury (CAAKI),

Iodine-based CT contrast ready for scanning with a Canon Aquilion One 320-slice CT system at Northwestern Medicine Central DuPage Hospital in the Chicago suburbs.

Feature | Contrast Media | May 31, 2019 | Dave Fornell, Editor
Iodine-based contrast agents used in c
DyeMINISH Multi-center Global Patient Registry Launched
News | Contrast Media | May 09, 2019
Osprey Medical announced the launch of DyeMINISH, a global patient registry to evaluate the ongoing safety and...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
Overlay Init